Compare CVNA & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVNA | BDX |
|---|---|---|
| Founded | 2012 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.9B | 51.5B |
| IPO Year | 2017 | 1995 |
| Metric | CVNA | BDX |
|---|---|---|
| Price | $397.31 | $152.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 13 |
| Target Price | ★ $439.67 | $186.00 |
| AVG Volume (30 Days) | 2.5M | ★ 2.8M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.89% |
| EPS Growth | ★ 431.45 | N/A |
| EPS | ★ 8.45 | 1.34 |
| Revenue | $20,322,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $34.66 | N/A |
| Revenue Next Year | $23.38 | $3.02 |
| P/E Ratio | ★ $47.19 | $114.18 |
| Revenue Growth | ★ 48.63 | 8.24 |
| 52 Week Low | $267.18 | $143.00 |
| 52 Week High | $486.89 | $213.08 |
| Indicator | CVNA | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 49.67 |
| Support Level | $390.87 | N/A |
| Resistance Level | $411.27 | $159.79 |
| Average True Range (ATR) | 19.49 | 3.51 |
| MACD | -2.80 | 0.12 |
| Stochastic Oscillator | 59.93 | 60.20 |
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage. The foundation of the business is retail vehicle unit sales. This drives the majority of the revenue and allows the company to capture additional revenue streams associated with financing, VSCs, auto insurance and GAP waiver coverage, as well as trade-in vehicles.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.